Healthcare entity
All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Centers for Disease Control and Prevention (CDC), the most common co-covered peer. We currently track 1 Healthcare story that mention CSL Seqirus, all published on March 14, 2026.
Last mentioned: Mar 14, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Centers for Disease Control and Prevention (CDC), the most common co-covered peer. We currently track 1 Healthcare story that mention CSL Seqirus, all published on March 14, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 13 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering CSL Seqirus. Shared-story counts are live from our verified record — not editorial picks.
Preliminary CDC data indicates that the 2025-2026 influenza vaccine provided lower-than-expected protection, with effectiveness falling to approximately 32%. The findings highlight a significant mismatch between the vaccine's composition and the dominant H3N2 variant, sparking calls for faster manufacturing platforms.
Source: abc11.com · abc7ny.com
CSL Seqirus is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
